



DEL CATH TO REPORT FIRST QUARTER 2014 RESULTS ON MAY 7, 2014

April 30, 2014

NEW YORK, NY - April 30, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, May 7, 2014 at 4:30 p.m. ET to discuss its financial results for the first quarter of 2014 ended March 31, 2014, and provide an update on recent corporate progress.

The dial-in numbers for the conference call are 866-318-8612 (U.S. participants) and 617-399-5131 (international participants); both numbers require passcode 78860495. To access the live webcast, go to the Events & Presentations page on the Investor Relations section of the Company's website at <http://www.delcath.com/investors/events/>.

A taped replay of the call will be available beginning approximately two hours after the call's conclusion and will be available for seven days. Dial-in numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and International callers, respectively. The replay passcode for both U.S. and International callers is 52886168. An archived webcast will also be available at <http://www.delcath.com/investors/events/>.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe, our proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has initiated plans to investigate the Melphalan/HDS system for primary liver cancer.

Contact Information:

Investor Contact:	Media Contact:
Michael Polyviou/Patty Eisenhaur	John Carter
EVC Group	EVC Group
212-850-6020/951-316-0577	646-201-5431

###